dc.creatorSovino, Hugo
dc.creatorSir Petermann, Teresa
dc.creatorDevoto, Luigi
dc.date.accessioned2019-01-29T17:52:01Z
dc.date.available2019-01-29T17:52:01Z
dc.date.created2019-01-29T17:52:01Z
dc.date.issued2002
dc.identifierReproductive biomedicine online, Volumen 4, Issue 3, 2018, Pages 303-310
dc.identifier14726483
dc.identifier10.1016/S1472-6483(10)61821-4
dc.identifierhttps://repositorio.uchile.cl/handle/2250/163645
dc.description.abstractClomiphene can be used to treat anovulation due to hypothalamus or pituitary gland dysfunction, and it normalizes the luteal phase in stimulated patients. It can be used to estimate ovarian follicle reserve, and may be predictive of ovulation in women aged >/=35 years or with failed IVF. Contraindications include risk of congenital anomalies, chronic liver disease and visual disorders. Clomiphene may impair fertility through its effects on cervical mucus and in causing various endometrial dysfunctions. However, if clomiphene is administered in 50 mg doses, side-effects are avoided and efficacy is similar to that of a 100 mg dose, although daily dosages of 200 mg/day over 5 days can induce ovulation in approximately 70% of treated patients. Gonadotrophin concentrations increase up to days 5-9 when follicles are selected, and clomiphene is effective in patients with polycystic ovary syndrome (PCOS). Fifty percent of normal patients conceive, a value perhaps biased by the antagonistic eff
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceReproductive biomedicine online
dc.subjectReproductive Medicine
dc.subjectDevelopmental Biology
dc.titleClomiphene citrate and ovulation induction
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución